0001104659-23-122841.txt : 20231201
0001104659-23-122841.hdr.sgml : 20231201
20231201161644
ACCESSION NUMBER: 0001104659-23-122841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231130
FILED AS OF DATE: 20231201
DATE AS OF CHANGE: 20231201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Golembiewski Michael Joseph
CENTRAL INDEX KEY: 0001639479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 231459735
MAIL ADDRESS:
STREET 1: 7 TURTLE CT
CITY: FLEMINGTON
STATE: NJ
ZIP: 08822
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
tm2331921-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-11-30
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001639479
Golembiewski Michael Joseph
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 2ND FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-11-30
4
P
0
83000
1.2075
A
86450
D
The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $1.07 per share to $1.27 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.
Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
/s/ Michael Golembiewski
2023-12-01